

Prof. Ömer Fatih ÖLMEZ

Personal Information

Email: ofolmez@medipol.edu.tr

Web: <https://avesis.medipol.edu.tr/ofolmez>

Education Information

Expertise In Medicine, Bursa Uludağ University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2003 - 2009

Undergraduate, Ondokuz Mayıs University, Tıp Fakültesi, Tıp Pr., Turkey 1995 - 2001

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer**
KUTLU Y., Cekin R., AYDIN S., Shbair A. T. M., BİLİCİ A., Arici S., Oven B. B., AÇIKGÖZ Ö., Ozcan E., ÖLMEZ Ö. F., et al.
Current Problems in Cancer, vol.50, 2024 (SCI-Expanded)
- II. **Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study**
KUTLU Y., Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., Senocak Tasci E., Bas O., Dane F., SAKİN A., et al.
Cancers, vol.16, no.12, 2024 (SCI-Expanded)
- III. **A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy**
Kilickap S., Ozturk A., Karadurmus N., KORKMAZ T., Yumuk P. F., ÇİÇİN İ., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al.
Medicine, vol.103, no.21, 2024 (SCI-Expanded)
- IV. **Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study**
ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., Uslu R., Mandel N. M., YALÇIN Ş., Teomete M., et al.
Japanese journal of clinical oncology, vol.54, no.5, pp.562-568, 2024 (SCI-Expanded)
- V. **Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study**
Taşçı E. Ş., KUTLU Y., ÖLMEZ Ö. F., Mutlu A. U., Gündoğdu Y., Seyyar M., Şahin E., ÇABUK D., Majidova N., Uğurlu İ., et al.
Expert Opinion on Pharmacotherapy, vol.25, no.4, pp.477-484, 2024 (SCI-Expanded)
- VI. **Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes**
Yıldız A., BİLİCİ A., AÇIKGÖZ Ö., HAMDARD J., BASIM P., ÇAKIR T., ÇAKIR A., ÖLMEZ Ö. F., Gezen C., YILDIZ Ö.
Journal of Chemotherapy, 2024 (SCI-Expanded)
- VII. **Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience**
HAMDARD J., BİLİCİ A., Sakin A., Kahraman S., Yasin A. I., Kalaci E., Gokmen I., AÇIKGÖZ Ö., KUTLU Y., Sendur M. A. N., et al.
Journal of Chemotherapy, 2024 (SCI-Expanded)
- VIII. **Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant**

prostate cancer treated with abiraterone or enzalutamide

Goktas Aydin S, Kutlu Y, Muglu H, Aydin A, Acikgoz Ö, Hamdard J, Karci E, Bilici A, Olmez Ö. F., Yildiz Ö.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.93, pp.71-78, 2024 (SCI-Expanded)

- IX. **Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer**
GÖKTAŞ AYDIN S, BİLİCİ A, ÇALIŞ E, KUTLU Y, HAMDARD J, MUĞLU H, Fatih Olmez Ö. F., KARCI E., AÇIKGÖZ Ö.
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.124, 2023 (SCI-Expanded)
- X. **Major and minor salivary gland cancers: A multicenter retrospective study**
Hacioglu M. B., ERDOĞAN B., Bardakcı M., Algin E., Gulbagcı B., Hacibekiroglu I., HAMDARD J., ÖLMEZ Ö. F., Akkus H., Oksuzoglu B., et al.
Head and Neck, vol.45, no.7, pp.1643-1653, 2023 (SCI-Expanded)
- XI. **Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous Ovarian Cancer**
Olmez F., Oglak S. C., Akgol S., ÖLMEZ Ö. F., BİLİCİ A., Akbayir O., Ozkose Z. G., Can E., Unal O., Sirinoglu H. A.
Journal of the College of Physicians and Surgeons Pakistan, vol.33, no.6, pp.66-672, 2023 (SCI-Expanded)
- XII. **Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice**
Tural D., Arslan C., Selcukbiricik F., ÖLMEZ Ö. F., Akar E., ERMAN M., ÜRÜN Y., Erdem D., Karadurmus N., Kilickap S.
Clinical Genitourinary Cancer, vol.21, no.3, pp.334-341, 2023 (SCI-Expanded)
- XIII. **Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy**
Kutlu Y., Aydin S. G., Bilici A., Oven B. B., Ölmez Ö. F., Açıkgöz Ö., Hamdard J.
Medicine (United States), vol.102, no.15, 2023 (SCI-Expanded)
- XIV. **Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study**
BİLİCİ A., ÖLMEZ Ö. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., ÇUBUKÇU E., Sendur M. A. N., AKSOY S., Erdem D., et al.
ACTA ONCOLOGICA, vol.62, no.4, pp.381-390, 2023 (SCI-Expanded)
- XV. **Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis**
Acikgoz O., Bilici A., Tataroglu Ozyukseler D., Göktaş Aydın S., Selcukbiricik F., Rzazade R., Ölmez Ö. F., Caglar H. B.
Turkish Journal of Medical Sciences, vol.53, no.4, pp.949-961, 2023 (SCI-Expanded)
- XVI. **Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer**
Erol V. B., GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., AÇIKGÖZ Ö., ÖLMEZ Ö. F., BASIM P.
Journal of Chemotherapy, vol.35, no.7, pp.662-670, 2023 (SCI-Expanded)
- XVII. **Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group**
Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., Uluç B. O., Demiray A. G., Erdem D., Demir B., et al.
Journal of Cancer Research and Clinical Oncology, vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)
- XVIII. **Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.**
GÖKTAŞ AYDIN S., Cakan Demirel B., BİLİCİ A., Topcu A., Aykan M. B., KAHRAMAN S., AKBIYIK I., Atci M. M., ÖLMEZ Ö. F., Yaren A., et al.
Current medical research and opinion, vol.38, no.10, pp.1751-1758, 2022 (SCI-Expanded)
- XIX. **The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer**
Aydin S. G., BİLİCİ A., ÖLMEZ Ö. F., Oven B. B., AÇIKGÖZ Ö., ÇAKIR T., BASIM P., ÇAKIR A., KUTLU Y., HAMDARD J.
Breast Care, vol.17, no.5, pp.470-479, 2022 (SCI-Expanded)
- XX. **Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint**

blockade therapies in patients with metastatic urothelial carcinoma

Tural D., Selçukbiricik F., ÖLMEZ Ö. F., Sümbül A. T., ERMAN M., Coşkun H. Ş., Artaç M., Kılıçkap S.
International Journal of Clinical Oncology, vol.27, no.3, pp.585-591, 2022 (SCI-Expanded)

- XXI. **Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study**
BİLİCİ A., Uysal M., Menekşe S., Akin S., Yildiz F., Turan M., SEZGİN GÖKSU S., Beypinar I., Sakalar T., Değirmenci M., et al.
Cancer Investigation, vol.40, no.2, pp.199-209, 2022 (SCI-Expanded)
- XXII. **Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer**
AÇIKGÖZ Ö., Cakan B., Demir T., BİLİCİ A., OVEN B. B., HAMDARD J., OLMUŞÇELİK O., ÖLMEZ Ö. F., ŞEKER M., YILDIZ Ö.
Medicine (United States), vol.100, no.44, 2021 (SCI-Expanded)
- XXIII. **Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey**
Cakan B., AÇIKGÖZ Ö., BİLİCİ A., Demir T., OVEN B. B., HAMDARD J., OLMUŞÇELİK O., ÖLMEZ Ö. F., ŞEKER M., YILDIZ Ö.
Journal of B.U.ON., vol.26, no.5, pp.1908-1917, 2021 (SCI-Expanded)
- XXIV. **Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences**
Tural D., ÖLMEZ Ö. F., Sümbül A. T., Artaç M., Özhan N., Akar E., Çakar B., Köstek O., EKENEL M., ERMAN M., et al.
European Urology Focus, vol.7, no.5, pp.1061-1066, 2021 (SCI-Expanded)
- XXV. **Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab**
Tural D., ÖLMEZ Ö. F., Sümbül A. T., Özhan N., Çakar B., Köstek O., EKENEL M., ERMAN M., Coşkun H. Ş., Selçukbiricik F., et al.
International Journal of Clinical Oncology, vol.26, no.8, pp.1506-1513, 2021 (SCI-Expanded)
- XXVI. **The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study**
Akdeniz N., Kaplan M. A., Uncu D., İNANÇ M., Kaya S., Dane F., Küçüköner M., Demirci A., BİLİCİ M., Durnalı A. G., et al.
International Journal of Colorectal Disease, vol.36, no.6, pp.1311-1319, 2021 (SCI-Expanded)
- XXVII. **Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence**
BAYRAMGİL A., BİLİCİ A., HAMDARD J., AÇIKGÖZ Ö., ŞEKER M., KILIÇASLAN F., KÖKSAL C., Buyukpinarbasili N., MAMMADOV E., GÖKTAŞ AYDIN S., et al.
Breast Journal, vol.27, no.1, pp.56-57, 2021 (SCI-Expanded)
- XXVIII. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients**
Peled N., Gillis R., Kılıçkap S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B., et al.
Lung Cancer, vol.148, pp.48-54, 2020 (SCI-Expanded)
- XXIX. **Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade**
ÖLMEZ Ö. F., Kinikoglu O., Yılmaz N. H., BİLİCİ A., ÇUBUKÇU E., ŞEKER M., ÇAKIR T., YILDIZ Ö., HAMDARD J.
Journal of Oncology Pharmacy Practice, vol.25, no.6, pp.1526-1530, 2019 (SCI-Expanded)
- XXX. **Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy**
BİLİCİ A., Selçukbiricik F., ŞEKER M., OVEN B. B., ÖLMEZ Ö. F., YILDIZ Ö., OLMUŞÇELİK O., HAMDARD J., AÇIKGÖZ Ö., ÇAKIR A., et al.
Oncology Research and Treatment, vol.42, no.4, pp.204-211, 2019 (SCI-Expanded)
- XXXI. **Association and Prognostic Significance of the Functional –1562C/T Polymorphism in the Promoter**

Region of MMP-9 in Turkish Patients with Gastric Cancer

Avcı N., Ture M., DELİGÖNÜL A., ÇUBUKÇU E., ÖLMEZ Ö. F., ŞAHİNTÜRK S., Topak A., Kurt E., EVRENSEL T., Şahin A. B., et al.

Pathology and Oncology Research, vol.21, no.4, pp.1243-1247, 2015 (SCI-Expanded)

XXXII. Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy

Avcı N., DELİGÖNÜL A., TOLUNAY Ş., ÇUBUKÇU E., ÖLMEZ Ö. F., Altmisdortoglu O., Tanriverdi O., Aksoy A., Kurt E., EVRENSEL T.

Journal of B.U.ON., vol.20, no.4, pp.994-1000, 2015 (SCI-Expanded)

Articles Published in Other Journals

- I. **The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data**
AYDIN S., ÖLMEZ Ö. F., Selvi O., Geredeli C., ÖZDEN F., BİLİCİ A., AÇIKGÖZ Ö., KARCI E., KUTLU Y., HAMDARD J., et al.
Journal of Gastrointestinal Cancer, vol.55, no.1, pp.227-236, 2024 (ESCI)
- II. **THE IMPORTANCE OF CLINICAL AND LABORATORY PARAMETERS OF BONE MARROW METASTASIS IN PATIENTS WITH SOLID MALIGNANCY-SINGLE CENTER EXPERIENCE**
Sadri S., J., Beköz H. S., Cakir A., ÖLMEZ Ö. F., Bilici A.
Karya Journal of Health Science, vol.4, no.3, pp.187-191, 2023 (Peer-Reviewed Journal)
- III. **Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study**
Aydın S. G., Kavak E. E., Topcu A., Bayramgil A., Akgul F., Kahraman S., Aykan M. B., Altıntaş Y. E., Helvacı K., Ürün Y., et al.
Biomolecules and Biomedicine, vol.23, no.6, pp.1089-1095, 2023 (Scopus)
- IV. **Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib**
ÖLMEZ Ö. F., BİLİCİ A., Gursoy P., ÇUBUKÇU E., Sakin A., KORKMAZ T., Cil I., Cakar B., Menekşe S., Demir T., et al.
Pulmonology, vol.29, no.6, pp.478-485, 2023 (Scopus)
- V. **The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients**
acıkgöz o., Göktaş Aydın S., Bilici A., Kutlu Y., Muglu H., Karci E., J., Mammadov E., ÖLMEZ Ö. F., yıldız Ö.
ACTA ONCOLOGICA TURCICA, vol.56, no.2, pp.153-160, 2023 (Peer-Reviewed Journal)
- VI. **SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT**
Aydın S., Kutlu Y., Muglu H., Açıkğöz Ö., Aydın A., Bilici A., Ölmez Ö. F., Unal D., Karci E., Yıldız Ö.
İstanbul Tıp Fakültesi Dergisi, vol.86, no.2, pp.117-122, 2023 (ESCI)
- VII. **The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side-Effects in Oncology Out-Patients**
Umar R. M., Ay Z. Y., Güven E., KARATAŞ KOÇBERBER E., ÖLMEZ Ö. F.
CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, vol.13, no.1, pp.212-217, 2023 (Peer-Reviewed Journal)
- VIII. **Treatment Management of Leptomeningeal and Brain Metastases as a First Recurrence Site in a Case with Germ Cell Testicular Tumor**
GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., ÖLMEZ Ö. F., CİLA A., ÜNAL D.
Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, vol.36, no.1, pp.77-80, 2022 (Peer-Reviewed Journal)
- IX. **High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer**
Tümör mikroçevresinde CD8'in yüksek ekspresyonu, yüksek dereceli seröz over kanserinde PD-1 ekspresyonu ve hasta sağkalımı ile ilişkilidir

Ölmez F., Oğlak S. C., ÖLMEZ Ö. F., Akbayır Ö., YILMAZ E., Akgöl S., Konal M., Seyhan N. A., Kinter A. K.
Turkish Journal of Obstetrics and Gynecology, vol.19, no.3, pp.246-256, 2022 (Scopus)

- X. **Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer**
AYDIN S. G., AÇIKGÖZ Ö., KUTLU Y., BİLİCİ A., HAMDARD J., ÖLMEZ Ö. F., YILDIZ Ö.
ACTA ONCOLOGICA TURCICA, vol.54, no.3, pp.281-290, 2021 (Peer-Reviewed Journal)
- XI. **Papilledema: Could it be an important clinical sign of leptomeningeal metastasis? Papilödem: Leptomeningeal metastazın önemli klinik işareti olabilir mi?**
Düz Ö. A., OLMUŞÇELİK O., Çadircı F., ÖLMEZ Ö. F.
Haseki Tıp Bulteni, vol.58, no.5, pp.441-446, 2020 (ESCI)
- XII. **Retrospective Evaluation of the Efficacy of Lapatinib Capecitabine in the Treatment of Metastatic Breast Cancer**
ÇUBUKÇU E., OCAK B., ÖLMEZ Ö. F., DELİGÖNÜL A., KAÇAN T.
Uludağ Üniversitesi Tıp Fakültesi Dergisi, vol.45, no.1, pp.29-32, 2019 (Peer-Reviewed Journal)
- XIII. **Kanserde Palyatif Tedaviler:Palyatif Kemoterapi Uygulamaları**
SAKİN A., ÖLMEZ Ö. F.
Türkiye Klinikleri, vol.3, no.3, pp.261-266, 2017 (Peer-Reviewed Journal)

Refereed Congress / Symposium Publications in Proceedings

- I. **Are pretreatment inflammation-based prognostic scores useful in predicting the outcomes of patients with ALK-positive NSCLC?**
ÖLMEZ Ö. F., BİLİCİ A., GÜRSOY P., ÇUBUKÇU E., YILDIZ O., SAKİN A., KORKMAZ T., ÇAKAR B., MENEKŞE S., AÇIKGÖZ O., et al.
IASLC 2019 World Conference on Lung Cancer, Barcelona, Spain, 7 - 10 September 2019, vol.14, pp.551-552
- II. **Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer**
BİLİCİ A., ÖLMEZ Ö. F., GÜRSOY P., ÇUBUKÇU E., YILDIZ O., SAKİN A., KORKMAZ T., ÇİL İ., ÇAKAR B., MENEKŞE S., et al.
IASLC 2019 World Conference on Lung Cancer, Barcelona, Spain, 7 - 10 September 2019, vol.14, pp.664-665
- III. **Özofagus Ca'lı hastada mideye migrate özofajial stentin endoloop yardımı ile çıkarılması.**
AKIN M. S., ÖLMEZ Ö. F., CANBALOĞLU ERKAN G., ERSAVAŞ C., SEKİ S., ÇEVİK L.
34. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 1 - 06 December 2017, pp.263
- IV. **Prognostic significance of positive lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectomy**
BİLİCİ A., ŞEKER M., USTAALIOĞLU BALA B. Ö., ÖLMEZ Ö. F., YILDIZ Ö., ÇAKIR A., ÖZKÖK ÇAĞLAR H. B., ÖNCEL M.
ESMO 19th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 28 June - 01 July 2017, vol.28, pp.35-36
- V. **Invaziv Lobüler Meme Karsinomunun Klinik Davranışı ve Metastaz Paterni: 4 Olgunun Değerlendirilmesi**
ÇALIŞ E., ÇAKIR A., AKHAN A., SAKA B., ALBAYRAK D., TÜRKMEN İ., ÖLMEZ Ö. F.
26. Ulusal Patoloji 7. Ulusal Sitopatoloji Kongresi, Antalya, Turkey, 2 - 06 November 2016
- VI. **Epiteloid Rabdomyosarkom: Yeni Tanımlanmış Nadir Bir Antite, Olgu Sunumu**
ÇAKIR A., AKHAN A., ORAN G., ÖLMEZ Ö. F., DERVİŞOĞLU S.
25. Ulusal Patoloji Kongresi 6. Sitopatoloji Kongresi, Bursa, Turkey, 14 - 17 October 2015